Ma family polypeptides and anti-Ma antibodies
AssigneeSloan-Kettering Institute for Cancer Research
InventorsJerome B. Posner, Josep O. Dalmau, Myrna R. Rosenfeld
Life of this patent
Estimating the term…
Abstract
Ma family polypeptides Ma1, Ma2, Ma3, Ma4 and Ma5 are disclosed, as are nucleic acids encoding the Ma family polypeptides, antibodies that bind to Ma family polypeptides, and methods of diagnosis of paraneoplastic syndromes, by assessing a test sample from an individual for the presence or absence, or amount, of antibodies to Ma family polypeptides.
Claims46
A method of diagnosing a neurologic disorder associated with the presence of a neoplasm in an individual, comprising assessing a test sample from the individual for the presence of antibodies to a Ma family polypeptide, wherein the Ma family polypeptide is selected from the group consisting of:
- a) a polypeptide that is expressed by the brain or testis, or both brain and testis, and that is recognized by antibodies that specifically bind to one or more polypeptides selected from the group consisting of:
- Ma1 (SEQ ID NO:4), Ma2 (SEQ ID NO:7), Ma3 (SEQ ID NO:9), Ma4 (SEQ ID NO:11) and Ma5 (SEQ ID NO:13),
- b) Ma1 (SEQ ID NO:4),
- c) Ma2 (SEQ ID NO:7),
- d) Ma3 (SEQ ID NO:9),
- c) Ma4 (SEQ ID NO:11), and
- f) Ma5 (SEQ ID NO:13),
- wherein the presence of antibodies to a Ma family polypeptide is indicative of the presence of the neurologic disorder associated with the presence of a neoplasm.
A method of diagnosing a neurologic disorder associated with the presence of a neoplasm in an individual, comprising assessing a test sample from the individual for the absence of antibodies to a Ma family polypeptide wherein the Ma family polypeptide is selected from the group consisting of:
- a) a polypeptide that is expressed by the brain or testis, or both brain and testis, and that is recognized by antibodies that specifically bind to one or more polypeptides selected from the group consisting of:
- Ma1 (SEQ ID NO:4), Ma2 (SEQ ID NO:7), Ma3 (SEQ ID NO:9), Ma4 (SEQ ID NO:11) and Ma5 (SEQ ID NO:13),
- b) Ma1 (SEQ ID NO:4),
- c) Ma2 (SEQ ID NO:7),
- d) Ma3 (SEQ ID NO:9),
- e) Ma4 (SEQ ID NO:11), and
- f) Ma5 (SEQ ID NO:13),
- wherein the absence of antibodies to a Ma family polypeptide is indicative of the absence of the neurologic disorder associated with the presence of a neoplasm.
A method of diagnosing a neurologic disorder associated with the presence of a neoplasm in an individual, comprising the steps of:
- a) contacting a test sample from the individual with a Ma family polypeptide sample, wherein the Ma family polypeptide is selected from the group consisting of:
- 1) a polypeptide that is expressed by the brain or testis, or both brain and testis, and that is recognized by antibodies that specifically bind to one or more polypeptides selected from the group consisting of:
- Ma1 (SEQ ID NO:4), Ma2 (SEQ ID NO:7), Ma3 (SEQ ID NO:9), Ma4 (SEQ ID NO:11) and Ma5 (SEQ ID NO:13),
- 2) Ma1 (SEQ ID NO:4),
- 3) Ma2 (SEQ ID NO:7),
- 4) Ma3 (SEQ ID NO:9),
- 5) Ma4 (SEQ ID NO:11), and
- 6) Ma5 (SEQ ID NO:13),
- under conditions that allow antibodies, of present, to blind to Ma family, polypeptide, thereby generating a compacted sample;
- and
- b) comparing the amount of anti-Ma family polypeptide antibody in the contacted sample with a reference amount, wherein an amount of anti-Ma family polypeptide antibodies in the contacted sample that is equal to, or greater than, the reference amount, is indicative of the presence of the neurologic disorder associated with the presence of a neoplasm.
A method of diagnosing a neurologic disorder associated with the presence of a neoplasm in an individual, comprising the steps of:
- a) contacting a test sample from the individual with a Ma family polypeptide sample, wherein the Ma family polypeptide is selected from the group consisting of:
- 1) a polypeptide that is expressed by the brain or testis, or both brain and testis, and that is recognized by antibodies that specifically bind to one or more polypeptides selected from the group consisting of:
- Ma1 (SEQ ID NO:4), Ma2 (SEQ ID NO:7), Ma3 (SEQ ID NO:9), Ma4 (SEQ ID NO:11) and Ma5 (SEQ ID NO:13),
- 2) Ma1 (SEQ ID NO:4),
- 3) Ma2 (SEQ ID NO:7),
- 4) Ma3 (SEQ ID NO:9),
- 5) Ma4 (SEQ ID NO:11), and
- 6) Ma5 (SEQ ID NO:13),
- under conditions that allow antibodies, if present, to bind to Ma family polypeptide, thereby generating a contacted sample;
- and
- b) comparing the amount of anti-Ma family polypeptide antibody in the contacted sample with a reference amount, wherein an amount of anti-Ma family polypeptide antibodies in the contacted sample that is less than the reference amount is indicative of the absence of the neurologic disorder associated with the presence of a neoplasm.
A method of diagnosing a neurologic disorder associated with the presence of a neoplasm in an individual, comprising the steps of:
- a) contacting a test sample from the individual with a Ma family polypeptide sample, wherein the Ma family polypeptide is selected from the group consisting of:
- 1) a polypeptide that is expressed by the brain or testis, or both brain and testis, and that is recognized by antibodies that specifically bind to one or more polypeptides selected from the group consisting of:
- Ma1 (SEQ ID NO:4), Ma2 (SEQ ID NO:7), Ma3 (SEQ ID NO:9), Ma4 (SEQ ID NO:11) and Ma5 (SEQ ID NO:13),
- 2) Ma1 (SEQ ID NO:4),
- 3) Ma2 (SEQ ID NO:7),
- 4) Ma3 (SEQ ID NO:9),
- 5) Ma4 (SEQ ID NO:11), and
- 6) Ma5 (SEQ ID NO:13),
- under conditions that allow antibodies, if present, to bind to Ma family polypeptide, thereby generating a contacted sample;
- b) determining the amount of anti-Ma family polypeptide antibody in the contacted sample;
- and
- c) comparing the amount of anti-Ma family polypeptide antibody in the contacted sample with the amount of anti-Ma family polypeptide antibody in at least one comparable negative control sample, wherein an amount of anti-Ma family polypeptide antibody in the contacted sample flat is significantly greater than an amount of anti-Ma family polypeptide antibody in a comparable negative control sample is indicative of the presence of the neurologic disorder associated with the presence of a neoplasm.
A method or diagnosing a neurologic disorder associated with the presence of a neoplasm in an individual, comprising the steps of:
- a) contacting a test sample from the individual with a Ma family polypeptide sample, wherein the Ma family polypeptide is selected from the group consisting of:
- 1) a polypeptide that is expressed by the brain or testis, or both brain and testis, and that is recognized by antibodies that specifically bind to one or more polypeptides selected from the group consisting of:
- Ma1 (SEQ ID NO:4), Ma2 (SEQ ID NO:7), Ma3 (SEQ ID NO:9), Ma4 (SEQ ID NO:11) and Ma5 (SEQ ID NO:13),
- 2) Ma1 (SEQ ID NO:4),
- 3) Ma2 (SEQ ID NO:7),
- 4) Ma3 (SEQ I) NO:9),
- 5) Ma4 (SEQ ID NO:11), and
- 6) Ma5 (SEQ ID NO:13),
- under conditions that allow antibodies, if present, to bind to Ma Family polypeptide thereby generating a contacted sample;
- b) determining the amount of anti-Ma family polypeptide antibody in the contacted sample;
- and
- c) comparing the amount of anti-Ma family polypeptide antibody in the contacted sample with the amount of anti-Ma family polypeptide antibody in at least one comparable negative control sample, wherein an amount of anti-Ma family polypeptide antibody in the contacted sample that is not significantly greater than an amount of anti-Ma family polypeptide antibody in a comparable negative control sample is indicative of the absence of the neurologic disorder associated with the presence of a neoplasm.
A method of diagnosing a neoplasm in an individual, comprising assessing a test sample from the individual for the presence of antibodies to a Ma family polypeptide, wherein the Ma family polypeptide is selected from the group consisting of:
- a) a polypeptide that is expressed by the brain or testis, or both brain and testis, and that is recognized by antibodies that specifically bind to one or more polypeptides selected from the group consisting of:
- Ma1 (SEQ ID NO:4), Ma2 (SEQ ID NO:7), Ma3 (SEQ ID NO:9), Ma4 (SEQ ID NO:11) and Ma5 (SEQ ID NO:13),
- b) Ma1 (SEQ ID NO:4),
- c) Ma2 (SEQ ID NO:7),
- d) Ma3 (SEQ ID NO:9),
- e) Ma4 (SEQ ID NO:11), and
- f) Ma5 (SEQ ID NO:13),
- wherein the presence of antibodies to a Ma family polypeptide is indicative of the presence of a neoplasm.
A method of diagnosing a neoplasm in an individual, comprising assessing a test sample from the individual for the presence or absence of antibodies to a Ma family polypeptide, wherein the Ma family polypeptide is selected from the group consisting of:
- a) a polypeptide that is expressed by the brain or testis, or both brain and testis, and that is recognized by antibodies that specifically bind to one or more polypeptides selected from the group consisting of:
- Ma1 (SEQ ID NO:4), Ma2 (SEQ ID NO;7), Ma3 (SEQ ID NO:9), Ma4 (SEQ ID NO:11) and Ma5 (SEQ ID NO:13),
- b) Ma1 (SEQ ID NO:4),
- a) Ma2 (SEQ ID NO:7),
- d) Ma3 (SEQ ID NO:9),
- e) Ma4 (SEQ ID NO:11), and
- f) Ma5 (SEQ ID NO:13),
- wherein the absence of antibodies to a Ma family polypeptide is indicative of the absence of a neoplasm.
A kit for use in diagnosis of a neurologic disorder associated with the presence of a neoplasm, comprising
- a) a Ma family polypeptide sample, wherein the Ma family polypeptide is selected from the group consisting of:
- 1) a polypeptide that is expressed by the brain or testis, or both brain and tests, and that is recognized by antibodies that specifically bind to one or more polypeptides selected from the group consisting of:
- Ma1 (SEQ ID NO:4), Ma2 (SEQ ID NO:7), Ma3 (SEQ ID NO:9), Ma4 (SEQ ID NO:11) and Ma5 (SEQ ID NO, 13),
- 2) Ma1 (SEQ ID NO:4),
- 3) Ma2 (SEQ ID NO:7),
- 4) Ma3 (SEQ ID NO:9),
- 5) Ma4 (SEQ ID NO:11), and
- 6) Ma5 (SEQ ID NO:13), b) a detector antibody that binds to anti-Ma family polypeptide antibody.
Dependencies are inferred from the claim text.